Revvity, Inc. · NYSE:RVTY
Revvity — PerkinElmer — Q2 2021 Earnings Presentation
7 slides from Revvity's earnings presentation, Jul 26, 2021
Slide 1: 2Q21 Earnings Presentation
2Q21 Earnings Presentation July 26, 2021
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: 2Q '21 Financial Results
2Q ‘21 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights Growth 41% Margin 535bps Growth 81% DAS Adjusted Revenue: $1.23 billion; +51% y/y 42% +DD • Organic: +41%; M&A: +6%; FX: +5% DX 58% • COVID: $365 million vs. $196 million in 2Q20 +DD • Non-COVID: +28% organi
Slide 4: Discovery & Analytical Solutions
DISCOVERY & ANALYTICAL SOLUTIONS 2Q21 Performance ✓ DD organic growth with Pharma/Biotech Food* Life up DD and Acad/Gov’t up DD Sciences ✓ Discovery (+DD) and Analytical (+DD) • +31% reported growth drove Pharma/Biotech performance • Organic: +22%; M&A: +6%; FX: +4% • All three regions posted at lea
Slide 5: Diagnostics
DIAGNOSTICS 2Q21 Performance ✓ DD organic growth driven by clinical Applied Reproductive diagnostics franchise Genomics Health • +70% reported growth ✓ Ongoing birth rate pressures offset by ImmunoDx improved utilization & menu expansion • Organic: +59%; M&A: +6%; FX: +5% • Non-COVID diagnostics +40
Slide 6: Updated Financial Guidance
UPDATED FINANCIAL GUIDANCE 3Q21 Guidance 2021 UPDATE • Adjusted Revenue: $1.00 billion; +4% reported growth • Adjusted Revenue: $4.57 billion; 21% reported growth • Organic: -5%; M&A +7%; FX +2% • Organic: +12%; M&A +6%; FX +3% Assumptions COVID vs. Non-COVID Outlook Assumptions COVID vs. Non-COVID
Slide 7: Innovating for a healthier world
INNOVATING for a healthier world Steve Willoughby | Vice President, Investor Relations | steve.willoughby@perkinelmer.com 7